Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France

Condition(s) targeted: Heart Failure; Cohort Study

Intervention: Candesartan (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Stephane Bouee, MD, MSc, Principal Investigator, Affiliation: CEMKA EVAL - Bourg La Reine - France
Luc Hittinger, MD, Prof, Study Chair, Affiliation: Hôpital Henri Mondor - Service de cardiologie - Créteil - France

Overall contact:
AstraZeneca France MC Clinical Study Information, Phone: + 33 1 41 29 40 25, Email: florence.thomas@astrazeneca.com

The purpose of this study is to describe the way candesartan is used in heart failure treatment in France (treatment initiation and monitoring), treatment stops occurrence and reasons for and patients clinical evolution

Official title: Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France

Study design: Cohort, Prospective

Primary outcome: Profile of patients treated with candesartan for heart failure

Secondary outcome:

Percentage of patients taking correctly its treatment : indication, contraindication, drug titration, treatment monitoring

Percentage of patients stopping its treatment and reasons why

Percentage of hospitalisations due to heart failure and cardiovascular deaths

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- outpatients to whom candesartan has been initiated for less than 30 days or during the

consultation to treat heart failure

Exclusion Criteria:

- patients included in a clinical trial the last 30 days before consultation

- patients unable to answer the questions for linguistic or cognitive reasons

- patients who will be difficult to follow during the one year study

AstraZeneca France MC Clinical Study Information, Phone: + 33 1 41 29 40 25, Email: florence.thomas@astrazeneca.com

Research Site, Chongqing, China; Not yet recruiting

Research Site, Shanghai, China; Not yet recruiting

Research Site, Hefei, Anhui, China; Not yet recruiting

Research Site, Fuzhou, Fujian, China; Not yet recruiting

Research Site, Guangzhou, Guangdong, China; Not yet recruiting

Research Site, Shenzhen, Guangdong, China; Not yet recruiting

Research Site, Xiamen, Guangdong, China; Not yet recruiting

Research Site, Zhongshan, Guangdong, China; Not yet recruiting

Research Site, Zhengzhou, Henan, China; Not yet recruiting

Research Site, Wuhan, Hubei, China; Not yet recruiting

Research Site, Changsha, Hunan, China; Not yet recruiting

Research Site, Nanjing, Jiangsu, China; Not yet recruiting

Research Site, Suzhou, Jiangsu, China; Not yet recruiting

Research Site, Wuxi, Jiangsu, China; Not yet recruiting

Research Site, Nanchang, Jiangxi, China; Not yet recruiting

Research Site, Jinan, Shandong, China; Not yet recruiting

Research Site, Qingdao, Shandong, China; Recruiting

Research Site, Taiyuan, Shanxi, China; Not yet recruiting

Research Site, Xi an, Shanxi, China; Not yet recruiting

Research Site, Chengdu, Sichuan, China; Not yet recruiting

Research Site, Kunming, Yunnan, China; Not yet recruiting

Research Site, Hangzhou, Zhejiang, China; Not yet recruiting

Research Site, Ningbo, Zhejiang, China; Not yet recruiting

Research Site, Rui an, Zhejiang, China; Not yet recruiting

Research Site, Wenzhou, Zhejiang, China; Not yet recruiting

Starting date: February 2008
Ending date: March 2010
Last updated: May 15, 2008